antibiotics discovery
Cent. Eur. J. Biol. • 8(10) • 2013 • 943-957
DOI: 10.2478/s11535-013-0209-6
Central European Journal of Biology
New perspectives on antibacterial drug research
Review Article
Joanna Ziemska, Aleksandra Rajnisz, Jolanta Solecka*
Laboratory of Biologically Active Compounds,
National Institute of Public Health - National Institute of Hygiene,
00-791 Warsaw, Poland
Received 14 March 2013; Accepted 10 May 2013
Abstract: Bacterial resistance to commonly used antibiotics is constantly increasing. Bacteria particularly dangerous for human life are methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and fluoroquinolone-resistant
Pseudomonas aeruginosa. Hence, there is an incessant need for developing compounds with new modes of action and seeking alternate drug targets. In this review, the authors discuss the current situation of antibacterial medicines and present data on new antibiotic targets. Moreover, alternatives to antibiotics, such as bacteriophages, antimicrobial peptides and monoclonal antibodies, are presented. The authors also draw attention to the valuable features of natural sources in developing antibacterial compounds.
The need to prevent and control infections as well as the reasonable use of currently available antibiotics is also emphasized.
Keywords: Bacterial resistance • Antibacterial compound • Drug discovery • Target • Antimicrobial peptides
© Versita Sp. z o.o.
1. Introduction
The use of antibiotics, especially the excessive and indiscriminative use, both in medicine and veterinary science has contributed to the emergence of drug resistant organisms. Antimicrobial drug resistance constitutes a growing problem worldwide [1]. Infections caused by resistant pathogens result in increased mortality and morbidity among human and animal populations. In addition, pathogenic microorganisms, including Staphylococcus aureus, Streptococcus pneumoniae and Clostridium difficile, contribute
DOI: 10.2478/s11535-013-0209-6
Central European Journal of Biology
New perspectives on antibacterial drug research
Review Article
Joanna Ziemska, Aleksandra Rajnisz, Jolanta Solecka*
Laboratory of Biologically Active Compounds,
National Institute of Public Health - National Institute of Hygiene,
00-791 Warsaw, Poland
Received 14 March 2013; Accepted 10 May 2013
Abstract: Bacterial resistance to commonly used antibiotics is constantly increasing. Bacteria particularly dangerous for human life are methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and fluoroquinolone-resistant
Pseudomonas aeruginosa. Hence, there is an incessant need for developing compounds with new modes of action and seeking alternate drug targets. In this review, the authors discuss the current situation of antibacterial medicines and present data on new antibiotic targets. Moreover, alternatives to antibiotics, such as bacteriophages, antimicrobial peptides and monoclonal antibodies, are presented. The authors also draw attention to the valuable features of natural sources in developing antibacterial compounds.
The need to prevent and control infections as well as the reasonable use of currently available antibiotics is also emphasized.
Keywords: Bacterial resistance • Antibacterial compound • Drug discovery • Target • Antimicrobial peptides
© Versita Sp. z o.o.
1. Introduction
The use of antibiotics, especially the excessive and indiscriminative use, both in medicine and veterinary science has contributed to the emergence of drug resistant organisms. Antimicrobial drug resistance constitutes a growing problem worldwide [1]. Infections caused by resistant pathogens result in increased mortality and morbidity among human and animal populations. In addition, pathogenic microorganisms, including Staphylococcus aureus, Streptococcus pneumoniae and Clostridium difficile, contribute
References: Chemother., 2011, 66, 1941-1944 Brötz-Oesterhelt H., Sass P., Postgenomic strategies in antibacterial drug discovery, Future Microbiol., 2010, 5, 1553-1579 for drug discovery, J. Med.Chem., 2008, 51, 28712878 McCluskey S.M., Knapp Ch.W., Predicting Microbiol., 2011, 2, 1-2 Peterson L.R., Bad Bugs, No Drugs: No ESKAPE revisited, Clin. Infect. Dis., 2009, 49, 992-993 Rice L.B., Federal funding for the Study of antibacterial agents among key bacterial pathogens, Ann.N.Y.Acad.Sci, 2013, 1277, 1-7 vulnerable patients, Cleve Clin J Med., 2013, 80, 225-33 diseases society of America, Clin. Infect. Dis., 2009, 48, 1-12 to 2010, J. Nat. Prod., 2012, 75, 311–335 Devasahayam G., Scheld W.M., Hoffman P.S.,